ShenLuo Medical, an Innovative Neuromodulation Company, Completes Series A Funding Round Led by CICC CH Fund

VCBeat was the first to learn that, in September 2021,SNEURO MEDICAL has completed its Series A financing round, exclusively led by the CICC Chuanhe Fund under CICC Capital. The proceeds from this round will be primarily used for team building, as well as the research, development, and regulatory registration of its in-development product—the Spinal Cord Stimulator (SCS).

SNEURO MEDICAL was established in December 2018 and is located in the Artificial Intelligence Town, Yuhang District, Hangzhou, Zhejiang Province.Based on the research and development of innovative technologies in the field of neuromodulation, the company is committed to providing patients with pain, epilepsy, heart failure, and other conditions with more advanced and effective therapeutic solutions to improve their quality of life.

To date, the company holds nearly 20 patents across various categories. It has assembled a multidisciplinary team of professionals specializing in microelectronics, information technology, mechatronics, clinical medicine, and other related fields, alongside a group of senior scholars and industry experts with extensive experience in the field of neurostimulation. Furthermore, the company has established a GMP-compliant R&D laboratory and a biochemical testing laboratory to ensure a standardized and controllable environment for research, development, and production.

The products currently under development are Class III active implantable neurological medical devices—Spinal Cord Stimulator (SCS) and short-term implantable Peripheral Nerve Stimulator (PNS).Designed for patients with chronic refractory pain,The product features integrated high, medium, and low frequencies with adaptive capabilities,Dozens of core technologies, including fast long-distance wireless charging technology, delivering an enhanced patient experience. Furthermore, the company has established in-depth collaborations with renowned pain research laboratories both domestically and internationally. Leveraging extensive clinical resources and guided by clinical needs, it has laid a solid foundation for advancing product R&D and driving subsequent market commercialization.

Tong Xuanzi, Head of the CICC Chuanhe Fund, stated:“CICC Chuanhe Fund supports and is highly optimistic about the exploration of neuromodulation therapy across multiple disease areas. SNEURO MEDICAL focuses on pain management, effectively treating severe and refractory pain and addressing existing clinical unmet needs. CICC Chuanhe Fund will provide robust support and long-term partnership to help the company contribute to pain treatment in China, and looks forward to its future expansion into other therapeutic fields to benefit more patients.”

Wang Shoudong, founder of SNEURO MEDICAL, also stated:“Securing this round of financing represents a strong endorsement by the CICC Chuanhe Fund of SNEURO MEDICAL’s professional expertise, industry influence, and growth potential. Moving forward, SNEURO MEDICAL will continue to be guided by product R&D. Building upon our SCS and PNS solutions for pain management, our product portfolio will rapidly expand into fields such as DBS and heart failure, thereby establishing a comprehensive and robust neuromodulation lineup. We are committed to driving the advancement of the neuromodulation industry and continuously empowering the sector. Let us join hands and forge ahead to create a brilliant future together!”

The CICC Chuanhe Equity Investment Fund was established in 2020, with CICC Capital Management Co., Ltd. (hereinafter referred to as “CICC Capital”) serving as the fund manager and general partner. The fund will deeply implement the “One CICC” development strategy, fully leveraging CICC’s professional synergistic advantages across “Research + Investment + Investment Banking.” Unconstrained by geographical boundaries, it will comprehensively invest in the fields of technological innovation, healthcare, and consumption upgrading, aiming to deliver optimal investment returns to investors while accelerating the rapid growth of high-potential, high-growth enterprises.